These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

740 related articles for article (PubMed ID: 32758491)

  • 21. Impact of 21-Gene Expression Assay on Staging Estrogen Receptor-Positive HER2-Negative Breast Cancer.
    Breaux A; Turner B; Wu X; Rai SN; Riley EC; Mandadi M; Sanders MA
    Clin Breast Cancer; 2019 Feb; 19(1):e261-e269. PubMed ID: 30509870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients.
    Wu J; Fang Y; Lin L; Fei X; Gao W; Zhu S; Zong Y; Chen X; Huang O; He J; Zhu L; Chen W; Li Y; Shen K
    Oncotarget; 2017 Jun; 8(24):38706-38716. PubMed ID: 28404972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of Ki-67 proliferative index with oncotype DX recurrence score in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer with low-burden axillary nodal disease - a review of 137 cases.
    Saad Abdalla Al-Zawi A; Anichkina KA; Elamass M; Aladili Z
    Pol J Pathol; 2024; 75(1):8-18. PubMed ID: 38741425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
    Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
    Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer.
    Wesseling J; Tinterri C; Sapino A; Zanconati F; Lutke-Holzik M; Nguyen B; Deck KB; Querzoli P; Perin T; Giardina C; Seitz G; Guinebretière JM; Barone J; Dekker L; de Snoo F; Stork-Sloots L; Roepman P; Watanabe T; Cusumano P
    Virchows Arch; 2016 Sep; 469(3):297-304. PubMed ID: 27377889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concordance between semiquantitative immunohistochemical assay and oncotype DX RT-PCR assay for estrogen and progesterone receptors.
    O'Connor SM; Beriwal S; Dabbs DJ; Bhargava R
    Appl Immunohistochem Mol Morphol; 2010 May; 18(3):268-72. PubMed ID: 20186046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive markers in breast cancer: An update on ER and HER2 testing and reporting.
    Calhoun BC; Collins LC
    Semin Diagn Pathol; 2015 Sep; 32(5):362-9. PubMed ID: 25770732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlating Predicted Adjuvant Therapy Benefit and Risk of Recurrence Between Breast Cancer Index (BCI) and the 21-Gene Oncotype DX Recurrence Score (RS).
    Casasanta N; Patel R; Raymond S; Kier MW; Blanter J; Sohval S; Hovstadius M; Wu C; Zimmerman B; Cascetta K; Bagiella E; Tiersten A
    Clin Breast Cancer; 2024 Oct; 24(7):585-596. PubMed ID: 38971641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brief fixation enables same-day breast cancer diagnosis with reliable assessment of hormone receptors, E-cadherin and HER2/Neu.
    Halilovic A; Bulte J; Jacobs Y; Braam H; van Cleef P; Schlooz-Vries M; Werner A; Boelens O; Nagtegaal I; de Wilt H; Bult P
    J Clin Pathol; 2017 Sep; 70(9):781-786. PubMed ID: 28325747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay.
    Lin HK; Can T; Kahn A; Flannery CA; Hoag J; Akkunuri A; Bailey H; Baehner R; Pusztai L; Rozenblit M
    Oncologist; 2023 Oct; 28(10):e973-e976. PubMed ID: 37656608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy.
    Krystel-Whittemore M; Xu J; Brogi E; Ventura K; Patil S; Ross DS; Dang C; Robson M; Norton L; Morrow M; Wen HY
    Breast Cancer Res Treat; 2019 Aug; 177(1):61-66. PubMed ID: 31144151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence, Clinicopathologic Features, HER2 Fluorescence In Situ Hybridization Profile, and Oncotype DX Results of Human Epidermal Growth Factor Receptor 2-Low Breast Cancers: Experience From a Single Academic Center.
    Hu Y; Jones D; Zhao W; Tozbikian G; Wesolowski R; Parwani AV; Li Z
    Mod Pathol; 2023 Jul; 36(7):100164. PubMed ID: 36967073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data.
    Orucevic A; Bell JL; McNabb AP; Heidel RE
    Breast Cancer Res Treat; 2017 May; 163(1):51-61. PubMed ID: 28243897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data.
    Orucevic A; Bell JL; King M; McNabb AP; Heidel RE
    Breast; 2019 Aug; 46():116-125. PubMed ID: 31146185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HER-2, ER, PR status concordance in primary breast cancer and corresponding metastatic lesion in lymph node in Chinese women.
    Li MH; Hou CL; Wang C; Sun AJ
    Pathol Res Pract; 2016 Apr; 212(4):252-7. PubMed ID: 26899763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification.
    Allott EH; Geradts J; Sun X; Cohen SM; Zirpoli GR; Khoury T; Bshara W; Chen M; Sherman ME; Palmer JR; Ambrosone CB; Olshan AF; Troester MA
    Breast Cancer Res; 2016 Jun; 18(1):68. PubMed ID: 27349894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation between HER2 determined by fluorescence in situ hybridization and reverse transcription-polymerase chain reaction of the oncotype DX test.
    Dvorak L; Dolan M; Fink J; Varghese L; Henriksen J; Gulbahce HE
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):196-9. PubMed ID: 22914611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of Oncotype DX recurrence score using deep multi-layer perceptrons in estrogen receptor-positive, HER2-negative breast cancer.
    Baltres A; Al Masry Z; Zemouri R; Valmary-Degano S; Arnould L; Zerhouni N; Devalland C
    Breast Cancer; 2020 Sep; 27(5):1007-1016. PubMed ID: 32385567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Oncotype DX and Mammostrat risk estimations and correlations with histologic tumor features in low-grade, estrogen receptor-positive invasive breast carcinomas.
    Acs G; Kiluk J; Loftus L; Laronga C
    Mod Pathol; 2013 Nov; 26(11):1451-60. PubMed ID: 23743933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.